PHAT News and Press, Phathom Pharmaceuticals Inc. From 02/29/24

Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestina...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-16 16:37:46 ET Gainers: Iovance Biotherapeutics ( IOVA ) +4% . Microvision ( MVIS ) +3% . Iridium Communications  ( IRDM ) +3% . Playtika Holding  ( PLTK ) +2% . JetBlue Airways  ( JBLU ) +2% . Losers...

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.3% to $11.595 on volume of 119,263,238 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.8% to $4.3323 on volume of 111,414,526 shares SoundHound AI Inc. (SOUN) rose 0.0% to $3.7601 on volu...

One of the largest pharmacy benefit management (PBM) companies in the United States has added VOQUEZNA (vonoprazan) tablets to its national formularies for commercial plans, effective immediately FLORHAM PARK, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq...

2024-02-01 06:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fires...

2024-01-25 11:13:47 ET More on Phathom Pharmaceuticals Phathom Pharma Is A Buy Before July PDUFA Phathom Pharmaceuticals expands existing loan and security deal with Hercules Capital Phathom Pharma heartburn drug undergoes FDA review Read the full article o...

2024-01-10 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-01 06:41:03 ET Summary Phathom Pharmaceuticals' stock is down 35% from its August highs and is now trading at $9. The company has two approved indications for its drug vonoprazan and an upcoming PDUFA. Phathom has a cash balance of $213mn and a cash runway of 8-9 quart...